NCT00717678已完成3 期
A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF and Extended Release (XL) Tacrolimus /MMF in de Novo Kidney Transplant Recipients
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 73
- 主要终点
- The patient and graft survival rates at 6 month post-transplant
研究概览
简要总结
The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF in de novo kidney transplant recipients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has been fully informed and has signed an IRB approved informed consent form and is willing and able to follow study procedures
- •Patient is a recipient of a primary or retransplanted cadaveric or non-HLA-identical living kidney transplant
- •Patient must receive first oral dose of randomized study drug within 48 hours of transplant procedure
- •Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to enrollment or upon hospitalization
排除标准
- •Patient has previously received or is receiving an organ transplant other than a kidney
- •Patient has received a kidney transplant from a non-heart beating donor
- •Patient has received an ABO incompatible donor kidney
- •Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV)
- •Patient has a current malignancy or a history of malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully
- •Patient has significant liver disease, defined as having during the past 28 days continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 3 times the upper value of the normal range of the investigational site
- •Patient has an uncontrolled concomitant infection or any other unstable medical condition that could interfere with the study objectives
- •Patient is currently taking or has been taking an investigational drug in the 30 days prior to transplant
- •Patient is receiving everolimus or enteric coated mycophenolic acid at any time during the study
- •Patient has a known hypersensitivity to tacrolimus, mycophenolate mofetil or corticosteroids
- •Patient is pregnant or lactating
- •Patient is unlikely to comply with the visits scheduled in the protocol
- •Patient has any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication with the investigator
研究组 & 干预措施
Prograf-XL + MMF
Experimental
干预措施: Prograf-XL (Drug)
Prograf-XL + MMF
Experimental
干预措施: MMF (Drug)
Prograf + MMF
Active Comparator
干预措施: Prograf (Drug)
Prograf + MMF
Active Comparator
干预措施: MMF (Drug)
结局指标
主要结局
The patient and graft survival rates at 6 month post-transplant
时间窗: 6 months
次要结局
- Efficacy failure at 6-month posttransplant.(6 months)
- Incidence of biopsy confirmed acute rejection (Banff > 1) at 6 months and 12 months(6 months and 12 months)
- 1 year patient and graft survival(1 year)
研究者
相似试验
已完成
3 期
A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.Liver TransplantationTransplantation ImmunologyHost vs Graft ReactionNCT00720408Astellas Pharma Inc48
已完成
1 期
Fast & Fed Pharmacokinetic (PK) StudyBioavailabilityNCT00692016Bayer32
已完成
4 期
A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation PatientsLiver TransplantationNCT01018914Astellas Pharma Inc44
已完成
3 期
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I DisorderBipolar DisorderNCT00490971Johnson & Johnson Pharmaceutical Research & Development, L.L.C.768
已完成
3 期
A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With SchizophreniaSchizophreniaNCT00650793Johnson & Johnson Pharmaceutical Research & Development, L.L.C.473